Search
Blog Post
Esophageal Cancer Q&A with Dr. Fountzilas
… Esophageal Cancer Q&A with Dr. Fountzilas April is Esophageal Cancer Awareness Month. Here, Christos Fountzilas, MD , Associate Professor of Oncology and …
Blog Post
Can you have liver cancer and not know it?
… that is significantly damaged,” according to Christos Fountzilas, MD, FACP , Assistant Professor of GI Medical … fluke is a common cause of liver cancer, according to Dr. Fountzilas. More commonly, however, tumors or cancer in the …
Blog Post
New options for KRAS-associated cancers available at Roswell Park
… — or who develop resistance — to the drug,” says Christos Fountzilas, MD, FACP, Associate Professor of Oncology and … in my trial takes a different approach,” explains Dr. Fountzilas. “It binds to the KRAS molecule and breaks it …
Clinical Trial
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma
… Metastatic Pancreatic Ductal Adenocarcinoma III Fountzilas, Christos The purpose of this study is to compare …
Clinical Trial
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
… Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) III Fountzilas, Christos The purpose of this study is to evaluate …
Blog Post
What's New in Pancreatic Cancer Research?
… to treat it. “We should always have hope,” says Christos Fountzilas, MD, FACP , Department of Medical Oncology at … existing therapy. Some of the latest developments that Dr. Fountzilas considers exciting are new agents that target the …
Clinical Trial
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor…
… (FGFR)-altered, Chemotherapy- and FGFR Inhibitor… III Fountzilas, Christos This study is a Phase III, Randomized, …
Clinical Trial
A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
… Adults with Advanced or Metastatic Solid Tumors (OASIS) I Fountzilas, Christos This is an open-label, dose escalation …
Clinical Trial
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors
… with Locally Advanced or Metastatic Solid Tumors II Fountzilas, Christos This is a proof-of-concept study …
Clinical Trial
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2 Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or…
… Gastroesophageal Junction (GEJ), Esophageal, or… I Fountzilas, Christos This is a Phase 1, Open-Label, Dose …